Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis.
The therapeutic efficacy of human neutrophil peptide 1 (HNP-1) against experimental tuberculosis in mice on the basis of numbers of CFU has been examined. Mice infected with 1.5 x 10(4) CFU of Mycobacterium tuberculosis H(37)Rv and treated with different doses of HNP-1 injected subcutaneously exhibited significant clearance of bacilli from lungs, livers, and spleens. There were time- and dose-dependent decreases in the bacillary load in lungs, livers, and spleens of the HNP-1-treated animals compared to that in controls (untreated animals). These observations strongly suggest the therapeutic activity of HNP-1 against tuberculosis.
Sharma
S
S
Department of Biochemistry, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Verma
I
I
Khuller
G K
GK
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D006801:Humans; D008099:Liver / Q000382:microbiology; D008168:Lung / Q000382:microbiology; D051379:Mice; D008815:Mice, Inbred Strains; D013154:Spleen / Q000382:microbiology; D013997:Time Factors; D014376:Tuberculosis / Q000188:drug therapy* / Q000382:microbiology; D023084:alpha-Defensins / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D023084:alpha-Defensins; C406413:human neutrophil peptide 1